Targeting endocannabinoid degradation protects against experimental colitis in mice: Involvement of CB1 and CB2 receptors

Journal of Molecular Medicine

Volumn 86, Issue 8, 2008, Pages 925-936

  Storr, Martin A ^a   Keenan, Catherine M ^b   Emmerdinger, Dominik ^c   Zhang, Hong ^b   Yüce, Birol ^c   Sibaev, Andrei ^c   Massa, Federico ^d,e   Buckley, Nancy E ^f   Lutz, Beat ^e   Göke, Burkhard ^c   Brand, Stephan ^c   Patel, Kamala D ^b   Sharkey, Keith A ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF MUNICH   (Germany)

^d INSERM   (France)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

Author keywords

Colitis; Endocannabinoid system; FAAH; FAAH polymorphism; TNBS; URB597; VDM11

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; GENOMIC DNA; MESSENGER RNA; MYELOPEROXIDASE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; TRINITROBENZENESULFONIC ACID;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DEGRADATION; DISEASE COURSE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; CARBAMATES; COLITIS; CROHN DISEASE; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; HUMANS; MICE; MICE, INBRED C57BL; POLYMORPHISM, GENETIC; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; TRINITROBENZENESULFONIC ACID;

EID: 48149107173     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-008-0359-6     Document Type: Article

References (41)

1. AC Howlett F Barth TI Bonner G Cabral P Casellas WA Devane CC Felder M Herkenham K Mackie BR Martin R Mechoulam RG Pertwee 2002 International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 161 202
2. F Massa M Storr B Lutz 2005 The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract J Mol Med 83 944 954
3. M Storr B Yuce B Goeke 2006 Perspectives of cannabinoids in gastroenterology Z Gastroenterol 44 185 191
4. RG Pertwee 2001 Cannabinoids and the gastrointestinal tract Gut 48 859 867
5. M Duncan JS Davison KA Sharkey 2005 Review article: endocannabinoids and their receptors in the enteric nervous system Aliment Pharmacol Ther 22 667 683
6. F Massa G Marsicano H Hermann A Cannich K Monory BF Cravatt GL Ferri A Sibaev M Storr B Lutz 2004 The endogenous cannabinoid system protects against colonic inflammation J Clin Invest 113 1202 1209
7. A Sibaev F Massa B Yuce G Marsicano HA Lehr B Lutz B Goeke HD Allescher M Storr 2006 CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice J Mol Med 84 513 520
8. ES Kimball CR Schneider NH Wallace PJ Hornby 2006 Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium Am J Physiol Gastrointest Liver Physiol 291 G364 G371
9. N Ueda 2002 Endocannabinoid hydrolases Prostaglandins Other Lipid Mediat 68-69 521 534
10. G D'Argenio M Valenti G Scaglione V Cosenza I Sorrentini V Di Marzo 2006 Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation FASEB J 20 568 570
11. R Capasso I Matias B Lutz F Borrelli F Capasso G Marsicano N Mascolo S Petrosino K Monory M Valenti M Di V AA Izzo 2005 Fatty Acid amide hydrolase controls mouse intestinal motility in vivo Gastroenterology 129 941 951
12. AA Izzo G Aviello S Petrosino P Orlando G Marsicano B Lutz F Borrelli R Capasso S Nigam F Capasso M Di V 2008 Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon J Mol Med 86 89 98
13. BF Cravatt AH Lichtman 2002 The enzymatic inactivation of the fatty acid amide class of signaling lipids Chem Phys Lipids 121 135 148
14. MD Van Sickle LD Oland W Ho CJ Hillard K Mackie JS Davison KA Sharkey 2001 Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret Gastroenterology 121 767 774
15. G Marsicano CT Wotjak SC Azad T Bisogno G Rammes MG Cascio H Hermann J Tang C Hofmann W Zieglgänsberger V Di Marzo B Lutz 2002 The endogenous cannabinoid system controls extinction of aversive memories Nature 418 530 534
16. NE Buckley KL McCoy E Mezey T Bonner A Zimmer CC Felder M Glass A Zimmer 2000 Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor Eur J Pharmacol 396 141 149
17. JL Wallace CM Keenan 1990 An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis Am J Physiol 258 G527 G534
18. S Holt F Comelli B Costa CJ Fowler 2005 Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors Br J Pharmacol 146 467 476
19. D Fegley S Gaetani A Duranti A Tontini M Mor G Tarzia D Piomelli 2005 Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation J Pharmacol Exp Ther 313 352 358
20. JC Sipe K Chiang AL Gerber E Beutler BF Cravatt 2002 A missense mutation in human fatty acid amide hydrolase associated with problem drug use Proc Natl Acad Sci USA 99 8394 8399
21. KP Chiang AL Gerber JC Sipe BF Cravatt 2004 Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use Hum Mol Genet 13 2113 2119
22. JC Hoffmann NN Pawlowski AA Kuhl W Hohne M Zeitz 2002 Animal models of inflammatory bowel disease: an overview Pathobiology 70 121 130
23. M Neurath I Fuss W Strober 2000 TNBS-colitis Int Rev Immunol 19 51 62
24. L Grinspoon JB Bakalar 1995 Marihuana as medicine. A plea for reconsideration JAMA 273 1875 1876
25. RA Puffenbarger 2005 Molecular biology of the enzymes that degrade endocannabinoids Curr Drug Targets CNS Neurol Disord 4 625 631
26. A Mahadevan RK Razdan 2005 Further advances in the synthesis of endocannabinoid-related ligands AAPS J 7 E496 E502
27. MD Van Sickle M Duncan PJ Kingsley A Mouihate P Urbani K Mackie N Stella A Makriyannis D Piomelli JS Davison LJ Marnett V Di Marzo QJ Pittman KD Patel KA Sharkey 2005 Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 310 329 332
28. DC McVey PC Schmid HH Schmid SR Vigna 2003 Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1) J Pharmacol Exp Ther 304 713 722
29. M Storr 2007 TRPV1 in colitis: is it a good or a bad receptor? Neurogastroenterol Motil 19 625 629
30. P Holzer 2004 Vanilloid receptor TRPV1: hot on the tongue and inflaming the colon Neurogastroenterol Motil 16 697 699
31. F Massa A Sibaev G Marsicano H Blaudzun M Storr B Lutz 2006 Vanilloid receptor (TRPV-1) deficient mice show increased susceptibility to dinitrobenzene sulfonic acid-induced colitis J Mol Med 84 142 146
32. S Wirtz C Neufert B Weigmann MF Neurath 2007 Chemically induced mouse models of intestinal inflammation Nat Protoc 2 541 546
33. AA Izzo F Fezza R Capasso T Bisogno L Pinto T Iuvone G Esposito N Mascolo V Di Marzo F Capasso 2001 Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation Br J Pharmacol 134 563 570
34. RB Sartor 2006 Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis Nat Clin Pract Gastroenterol Hepatol 3 390 407
35. JC Sipe J Waalen A Gerber E Beutler 2005 Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH) Int J Obes (Lond) 29 755 759
36. J Seiderer S Brand KA Herrmann F Schnitzler R Hatz A Crispin S Pfennig SO Schoenberg B Goke P Lohse T Ochsenkuhn 2006 Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study Inflamm Bowel Dis 12 1114 1121
37. F Schnitzler S Brand T Staudinger S Pfennig K Hofbauer J Seiderer C Tillack B Goke T Ochsenkuhn P Lohse 2006 Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease Immunogenetics 58 99 106
38. JD Rioux RJ Xavier KD Taylor MS Silverberg P Goyette A Huett T Green P Kuballa MM Barmada LW Datta YY Shugart AM Griffiths SR Targan AF Ippoliti EJ Bernard L Mei DL Nicolae M Regueiro LP Schumm AH Steinhart JI Rotter RH Duerr JH Cho MJ Daly SR Brant 2007 Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis Nat Genet 39 596 604
39. RH Duerr 2007 Genome-wide association studies herald a new era of rapid discoveries in inflammatory bowel disease research Gastroenterology 132 2045 2049
40. C Libioulle E Louis S Hansoul C Sandor F Farnir D Franchimont S Vermeire O Dewit M de Vos A Dixon B Demarche I Gut S Heath M Foglio L Liang D Laukens M Mni D Zelenika A Van Gossum P Rutgeerts J Belaiche M Lathrop M Georges 2007 Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4 PLoS Genet 3 e58
41. M Camilleri P Carlson S McKinzie A Grudell I Busciglio D Burton K Baxter M Ryks AR Zinsmeister 2008 Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation Am J Physiol Gastrointest Liver Physiol 294 G13 G19